Civic Intelligence

AIDS Treatment Activists Coalition

EIN 57-1168208 • 501(c)3 • Denver, CO

Profile

The AIDS Treatment Activists Coalition (ATAC) is a national coalition of AIDS activists, many living with HIV/AIDS, working together to end the AIDS epidemic by advancing research on HIV/AIDS.

PO Box 9153Denver, CO 80209

www.aidstreatmentactivists.org

Siviq Scores

Precomputed percentiles relative to similar nonprofits. These scores are descriptive rather than judgmental.

Liabilities / Assets

59th percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

501(c)3 • <$500k nonprofits • Source year 2021

Liabilities / Revenue

61st percentile

0.00x

Tied with the lowest-debt nonprofits in its peer group.

501(c)3 • <$500k nonprofits • Source year 2021

Net Margin

1st percentile

-6516%

Higher net margin than 1% of similar nonprofits.

501(c)3 • <$500k nonprofits • Source year 2021

Top Officer Pay

84th percentile

$0

Higher top officer pay than 84% of similar nonprofits.

Top officer pay equals 0.0% of source-year revenue.

501(c)3 • <$500k nonprofits • Source year 2019

Asset Growth

43rd percentile

-5.7%

Faster asset growth than 43% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Revenue Growth

4th percentile

-99%

Faster revenue growth than 4% of similar nonprofits.

501(c)3 • <$500k nonprofits • Annualized from 2020 to 2021

Balance Sheet
Liabilities / Assets59th percentile

Assets

Down

$235,441

Down $14,269 (-5.7%) from 2020

Liabilities

-

No earlier filing loaded for comparison.

Net Assets

Down

$235,441

Down $14,269 (-5.7%) from 2020

Operations
Liabilities / Revenue61st percentileNet Margin1st percentile

Revenue

Down

$219

Down $17,923 (-99%) from 2020

Expenses

Down

$14,488

Down $24,428 (-63%) from 2020

Net Income

Up

-$14,269

Up $6,505 (+31%) from 2020

Trend Graphs

Balance Sheet Trend

Asset Growth43rd percentile

Grouped bars show assets, liabilities, and net assets across loaded filings.

$300K$200K$100K$0Assets 2010: $122,774Liabilities 2010: $3,159Net Assets 2010: $119,6152010Assets 2011: $164,391Liabilities 2011: $11,9462011Assets 2012: $185,924Liabilities 2012: $02012Assets 2013: $231,480Net Assets 2013: $231,4802013Assets 2014: $240,321Net Assets 2014: $240,3212014Assets 2015: $245,146Net Assets 2015: $245,1462015Assets 2016: $267,141Net Assets 2016: $267,1412016Assets 2017: $256,132Net Assets 2017: $256,1322017Assets 2018: $258,417Net Assets 2018: $258,4172018Assets 2019: $270,484Net Assets 2019: $270,4842019Assets 2020: $249,710Net Assets 2020: $249,7102020Assets 2021: $235,441Net Assets 2021: $235,4412021

Highlighted filing

2021

Assets$235,441
Liabilities-
Net Assets$235,441
Open 2021 Filing

Operations Trend

Revenue Growth4th percentile

Revenue, expenses, and net income by year, with the latest filing highlighted.

$150K$100K$50K$0-$50KRevenue 2010: $86,571Expenses 2010: $115,714Net Income 2010: -$29,1432010Revenue 2011: $98,828Expenses 2011: $65,998Net Income 2011: $32,8302011Revenue 2012: $61,379Expenses 2012: $27,900Net Income 2012: $33,4792012Revenue 2013: $86,547Expenses 2013: $40,991Net Income 2013: $45,5562013Revenue 2014: $38,327Expenses 2014: $29,486Net Income 2014: $8,8412014Revenue 2015: $46,413Expenses 2015: $41,588Net Income 2015: $4,8252015Revenue 2016: $37,707Expenses 2016: $15,712Net Income 2016: $21,9952016Revenue 2017: $36,304Expenses 2017: $47,313Net Income 2017: -$11,0092017Revenue 2018: $36,643Expenses 2018: $34,358Net Income 2018: $2,2852018Revenue 2019: $54,205Expenses 2019: $42,138Net Income 2019: $12,0672019Revenue 2020: $18,142Expenses 2020: $38,916Net Income 2020: -$20,7742020Revenue 2021: $219Expenses 2021: $14,488Net Income 2021: -$14,2692021

Highlighted filing

2021

Revenue$219
Expenses$14,488
Net Income-$14,269
Open 2021 Filing

Filings

Most recent year

2021 • Form 990EZDetailed filing. Detailed filing data is available for this year.

Open filing
Assets
$235,441
Liabilities
-
Net assets
$235,441
Revenue
$219
Expenses
$14,488
Net income
-$14,269
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2021Detailed filing. Detailed filing data is available for this year.$2.35$2.35$0.00$0.14$0.14
2020Detailed filing. Detailed filing data is available for this year.$2.50$2.50$0.18$0.39$0.21
2019Detailed filing. Detailed filing data is available for this year.$2.70$2.70$0.54$0.42$0.12
2018Detailed filing. Detailed filing data is available for this year.$2.58$2.58$0.37$0.34$0.02
2017Detailed filing. Detailed filing data is available for this year.$2.56$2.56$0.36$0.47$0.11
2016Detailed filing. Detailed filing data is available for this year.$2.67$2.67$0.38$0.16$0.22
2015Detailed filing. Detailed filing data is available for this year.$2.45$2.45$0.46$0.42$0.05
2014Detailed filing. Detailed filing data is available for this year.$2.40$2.40$0.38$0.29$0.09
2013Detailed filing. Detailed filing data is available for this year.$2.31$2.31$0.87$0.41$0.46
2012Summary only. Only limited summary data is available for this year.$1.86$0.00$0.61$0.28$0.33
2011Summary only. Only limited summary data is available for this year.$1.64$0.12$0.99$0.66$0.33
2010Facts available. Structured filing facts are available, but richer extracted sections are limited.$1.23$0.03$1.20$0.87$1.16$0.29
Latest Filing Detail
Jump To
Filing Snapshot
Filing Period
Jan 1, 2021 to Dec 31, 2021
Signed
Oct 25, 2022
Return Version
2021v4.0
Gross Receipts
$219
Mission and Program Overview

Mission

The AIDS Treatment Activists Coalition (ATAC) is a national coalition of AIDS activists, many living with HIV/AIDS, working together to end the AIDS epidemic by advancing research on HIV/AIDS.

Program Services

DescriptionGrantsExpenses
Drug Development Committee (DDC): The Drug Development Committee is ATAC's principal committee. The DDC works with government, academia and industry to expedite and promote ethical HIV research. During 2021, the DDC engaged with 4 major HIV pharmaceutical companies, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. The topics of these conferences included the following:- New drugs in the pipeline with better efficacy, safety profiles, long-acting agents, and ease of administration.- Continuing safety and efficacy updates on approved drugs, including the status of Phase IV post-marketing studies .- The design of clinical trials for both nave and heavily treatment experienced HIV patients, especially those with drug resistant mutations. - The necessity for inclusion of women, people of color and other underrepresented people in clinical trials and the necessity of conducting specific drug-drug interaction studies with new compounds to ensure underrepresented people will be eligible for trials and can participate safely- The need for collaboration among HIV drug companies so that fixed dosed combinations of the best drug cocktails will be available to people living with HIV.- Expanded Access programs to make promising new drugs available to the multi-drug resistant patients that need new drugs the most.- New strategies and therapies for eradicating HIV viral reservoirs, potentially leading to either a virtual cure or a sterilizing cure.- Strategies for treating co-morbidities, and other related issues dealing with chronic inflammation.- Aging with HIV and multiple complications involved. Collaborations:The DDC continued working with other national and international AIDS advocacy groups, collaborating with Treatment Action Group, Positively Aware, AVAC, NASTAD, NATAP, and also with our European counterpart, the European Community Advisory Board (ECAB), part of the European AIDS Treatment Group (EATG). DDC members continue to participate with ECAB/EATG members in meetings with HIV drug companies. In addition, ATAC continues to build a collaborative relationship with the Martin Delaney Cure Collaboratories at various academic institutions across the United States.Programs:In 2021, ATAC collaborated with several other organizations, and assembled a group of individuals with various expertises to create a Cureiculum program. ATAC invested resources to conduct the project. The Cureiculum created is a deck/program that various groups, CBOs, and individuals can use to conduct educational sessions and forums to provide education and information to the community on research and the work being conducted toward an HIV cure. This is now available for community use.$10,869-
Compensation and Service Providers
Top Officer Pay84th percentile

Employees

NameTitleFull / Part TimeBaseOtherTotal
MOISES AGOSTODirector-$0--
MURRAY PENNERPresident-$0--
DAVID PALMDirector-$0--
MICHAEL DOROSHVice President-$0--
ROBERT HUFFSecretary-$0--
ANDREW KAYTESDirector-$0--
RICHARD GUASCOTreasurer-$0--
Filing and Contact Details

Filer

Filer Name
Aids Treatment Activists Coalition
EIN
57-1168208
Phone
3037775737
Address
PO BOX 9153, DENVER, CO 80209

Signing Officer

Name
Michael Dorosh
Title
Director
Signed
2022-10-25
Discuss with paid preparer
Yes

Preparer

Firm
Dinowitz & Bove CPAs
Address
50 US Highway 9 Ste 103, Morganville, NJ 07751
Preparer
Frank Bove
Phone
2129730935
Supplemental Narrative

Additional Explanations

Other Expenses.1003

“Information Technology $360”

Other Expenses.1007

“Conferences, Conventions, and Meetings $869”

Other Expenses.1012

“Insurance $1340”

Other Expenses.1

“Consultants $10000”

Other Expenses.2

“Fees $397”

Other Expenses.3

“Telephone $82”

Raw XML Appendix168 raw XML fields

This appendix keeps the raw XML leaves available for debugging and edge-case review. The human report above is the primary experience.

Path#Value
IRS990EZ/ActivitiesNotPreviouslyRptInd0false
IRS990EZ/AddressChangeInd0X
IRS990EZ/BooksInCareOfDetail/PersonNm0MICHAEL DOROSH
IRS990EZ/BooksInCareOfDetail/PhoneNum03037775737
IRS990EZ/BooksInCareOfDetail/USAddress/AddressLine1Txt038 W MAPLE AVENUE
IRS990EZ/BooksInCareOfDetail/USAddress/CityNm0DENVER
IRS990EZ/BooksInCareOfDetail/USAddress/StateAbbreviationCd0CO
IRS990EZ/BooksInCareOfDetail/USAddress/ZIPCd080223
IRS990EZ/CashSavingsAndInvestmentsGrp/BOYAmt0249710
IRS990EZ/CashSavingsAndInvestmentsGrp/EOYAmt0235441
IRS990EZ/ChgMadeToOrgnzngDocNotRptInd0false
IRS990EZ/ContributionsGiftsGrantsEtcAmt0129
IRS990EZ/CostOfGoodsSoldAmt00
IRS990EZ/CostOrOtherBasisExpenseSaleAmt00
IRS990EZ/DonorAdvisedFndsInd0false
IRS990EZ/EngagedInExcessBenefitTransInd0false
IRS990EZ/ExcessOrDeficitForYearAmt0-14269
IRS990EZ/FeesAndOtherPymtToIndCntrctAmt01400
IRS990EZ/FiledScheduleAInd0true
IRS990EZ/ForeignFinancialAccountInd0false
IRS990EZ/ForeignOfficeInd0false
IRS990EZ/Form1120PolFiledInd0false
IRS990EZ/Form990TotalAssetsGrp/BOYAmt0249710
IRS990EZ/Form990TotalAssetsGrp/EOYAmt0235441
IRS990EZ/FundraisingGrossIncomeAmt00
IRS990EZ/GrossReceiptsAmt0219
IRS990EZ/InfoInScheduleOPartIInd0X
IRS990EZ/InvestmentIncomeAmt090
IRS990EZ/LobbyingActivitiesInd0false
IRS990EZ/MadeLoansToFromOfficersInd0false
IRS990EZ/MethodOfAccountingAccrualInd0X
IRS990EZ/NetAssetsOrFundBalancesBOYAmt0249710
IRS990EZ/NetAssetsOrFundBalancesEOYAmt0235441
IRS990EZ/NetAssetsOrFundBalancesGrp/BOYAmt0249710
IRS990EZ/NetAssetsOrFundBalancesGrp/EOYAmt0235441
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt01.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt11.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt21.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt31.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt41.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt51.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/AverageHrsPerWkDevotedToPosRt61.00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt00
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt10
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt20
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt30
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt40
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt50
IRS990EZ/OfficerDirectorTrusteeEmplGrp/CompensationAmt60
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm0MOISES AGOSTO
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm1MURRAY PENNER
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm2DAVID PALM
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm3MICHAEL DOROSH
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm4ROBERT HUFF
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm5ANDREW KAYTES
IRS990EZ/OfficerDirectorTrusteeEmplGrp/PersonNm6RICHARD GUASCO
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt0Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt1President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt2Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt3Vice President
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt4Secretary
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt5Director
IRS990EZ/OfficerDirectorTrusteeEmplGrp/TitleTxt6Treasurer
IRS990EZ/OperateHospitalInd0false
IRS990EZ/Organization501c3Ind0X
IRS990EZ/OrganizationDissolvedEtcInd0false
IRS990EZ/OrganizationHadUBIInd0false
IRS990EZ/OtherExpensesTotalAmt013048
IRS990EZ/PartVIHghstPdCntrctProfSrvcTxt0NONE
IRS990EZ/PartVIOfCompOfHghstPdEmplTxt0NONE
IRS990EZ/PoliticalCampaignActyInd0false
IRS990EZ/PrimaryExemptPurposeTxt0The AIDS Treatment Activists Coalition (ATAC) is a national coalition of AIDS activists, many living with HIV/AIDS, working together to end the AIDS epidemic by advancing research on HIV/AIDS.
IRS990EZ/PrintingPublicationsPostageAmt040
IRS990EZ/ProgramSrvcAccomplishmentGrp/DescriptionProgramSrvcAccomTxt0Drug Development Committee (DDC): The Drug Development Committee is ATAC's principal committee. The DDC works with government, academia and industry to expedite and promote ethical HIV research. During 2021, the DDC engaged with 4 major HIV pharmaceutical companies, Gilead Sciences, Janssen, Merck, and ViiV Healthcare. The topics of these conferences included the following:- New drugs in the pipeline with better efficacy, safety profiles, long-acting agents, and ease of administration.- Continuing safety and efficacy updates on approved drugs, including the status of Phase IV post-marketing studies .- The design of clinical trials for both nave and heavily treatment experienced HIV patients, especially those with drug resistant mutations. - The necessity for inclusion of women, people of color and other underrepresented people in clinical trials and the necessity of conducting specific drug-drug interaction studies with new compounds to ensure underrepresented people will be eligible for trials and can participate safely- The need for collaboration among HIV drug companies so that fixed dosed combinations of the best drug cocktails will be available to people living with HIV.- Expanded Access programs to make promising new drugs available to the multi-drug resistant patients that need new drugs the most.- New strategies and therapies for eradicating HIV viral reservoirs, potentially leading to either a virtual cure or a sterilizing cure.- Strategies for treating co-morbidities, and other related issues dealing with chronic inflammation.- Aging with HIV and multiple complications involved. Collaborations:The DDC continued working with other national and international AIDS advocacy groups, collaborating with Treatment Action Group, Positively Aware, AVAC, NASTAD, NATAP, and also with our European counterpart, the European Community Advisory Board (ECAB), part of the European AIDS Treatment Group (EATG). DDC members continue to participate with ECAB/EATG members in meetings with HIV drug companies. In addition, ATAC continues to build a collaborative relationship with the Martin Delaney Cure Collaboratories at various academic institutions across the United States.Programs:In 2021, ATAC collaborated with several other organizations, and assembled a group of individuals with various expertises to create a Cureiculum program. ATAC invested resources to conduct the project. The Cureiculum created is a deck/program that various groups, CBOs, and individuals can use to conduct educational sessions and forums to provide education and information to the community on research and the work being conducted toward an HIV cure. This is now available for community use.
IRS990EZ/ProgramSrvcAccomplishmentGrp/GrantsAndAllocationsAmt010869
IRS990EZ/ProhibitedTaxShelterTransInd0false
IRS990EZ/RelatedOrganizationCtrlEntInd0false
IRS990EZ/ScheduleBNotRequiredInd0X
IRS990EZ/SchoolOperatingInd0false
IRS990EZ/SpecialEventsDirectExpensesAmt00
IRS990EZ/StatesWhereCopyOfReturnIsFldCd0NY
IRS990EZ/SubjectToProxyTaxInd0false
IRS990EZ/TanningServicesProvidedInd0false
IRS990EZ/TaxImposedOnOrganizationMgrAmt00
IRS990EZ/TaxImposedUnderIRC4911Amt00
IRS990EZ/TaxImposedUnderIRC4912Amt00
IRS990EZ/TaxImposedUnderIRC4955Amt00
IRS990EZ/TaxReimbursedByOrganizationAmt00
IRS990EZ/TotalExpensesAmt014488
IRS990EZ/TotalProgramServiceExpensesAmt010869
IRS990EZ/TotalRevenueAmt0219
IRS990EZ/TransactionWithControlEntInd0false
IRS990EZ/TrnsfrExmptNonChrtblRltdOrgInd0false
IRS990EZ/WebsiteAddressTxt0www.aidstreatmentactivists.org
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearAmt0129
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus1YearAmt018000
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus2YearsAmt054000
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus3YearsAmt036040
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/CurrentTaxYearMinus4YearsAmt036100
IRS990ScheduleA/GiftsGrantsContriRcvd170Grp/TotalAmt0144269
IRS990ScheduleA/GovtFurnSrvcFcltsVl170Grp/TotalAmt00
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearAmt090
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus1YearAmt0142
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus2YearsAmt0205
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus3YearsAmt0603
IRS990ScheduleA/GrossInvestmentIncome170Grp/CurrentTaxYearMinus4YearsAmt0204
IRS990ScheduleA/GrossInvestmentIncome170Grp/TotalAmt01244
IRS990ScheduleA/OtherIncome170Grp/TotalAmt00
IRS990ScheduleA/PublicOrganization170Ind0X
IRS990ScheduleA/PublicSupportCY170Pct00.19180
IRS990ScheduleA/PublicSupportPY170Pct00.17640
IRS990ScheduleA/PublicSupportTotal170Amt027909
IRS990ScheduleA/SubstantialContributorsTotAmt0116360
IRS990ScheduleA/TaxRevLeviedOrgnztnlBnft170Grp/TotalAmt00
IRS990ScheduleA/TenPctFactsCrcmstncsTestCYInd0X
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearAmt0129
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus1YearAmt018000
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus2YearsAmt054000
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus3YearsAmt036040
IRS990ScheduleA/TotalCalendarYear170Grp/CurrentTaxYearMinus4YearsAmt036100
IRS990ScheduleA/TotalCalendarYear170Grp/TotalAmt0144269
IRS990ScheduleA/TotalSupportAmt0145513
IRS990ScheduleA/UnrelatedBusinessNetIncm170Grp/TotalAmt00
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt0Information Technology $360
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt1Conferences, Conventions, and Meetings $869
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt2Insurance $1340
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt3Consultants $10000
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt4Fees $397
IRS990ScheduleO/SupplementalInformationDetail/ExplanationTxt5Telephone $82
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc0Other Expenses.1003
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc1Other Expenses.1007
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc2Other Expenses.1012
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc3Other Expenses.1
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc4Other Expenses.2
IRS990ScheduleO/SupplementalInformationDetail/FormAndLineReferenceDesc5Other Expenses.3
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/AuthenticationAssuranceLevelCd0AAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/FederatedAssuranceLevelCd0FAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/IdentityAssuranceLevelCd0IAL1
ReturnHeader/AdditionalFilerInformation/TrustedCustomerGrp/TrustedCustomerCd02
ReturnHeader/BuildTS02022-09-23 18:48:47Z
ReturnHeader/BusinessOfficerGrp/DiscussWithPaidPreparerInd0true
ReturnHeader/BusinessOfficerGrp/PersonNm0MICHAEL DOROSH
ReturnHeader/BusinessOfficerGrp/PersonTitleTxt0Director
ReturnHeader/BusinessOfficerGrp/SignatureDt02022-10-25
ReturnHeader/Filer/BusinessName/BusinessNameLine1Txt0AIDS TREATMENT ACTIVISTS COALITION
ReturnHeader/Filer/BusinessNameControlTxt0AIDS
ReturnHeader/Filer/EIN0571168208
ReturnHeader/Filer/PhoneNum03037775737
ReturnHeader/Filer/USAddress/AddressLine1Txt0PO BOX 9153
ReturnHeader/Filer/USAddress/CityNm0DENVER
ReturnHeader/Filer/USAddress/StateAbbreviationCd0CO
ReturnHeader/Filer/USAddress/ZIPCd080209
ReturnHeader/PreparerFirmGrp/PreparerFirmEIN0020632187
ReturnHeader/PreparerFirmGrp/PreparerFirmName/BusinessNameLine1Txt0Dinowitz & Bove CPAs
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/AddressLine1Txt050 US Highway 9 Ste 103
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/CityNm0Morganville
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/StateAbbreviationCd0NJ
ReturnHeader/PreparerFirmGrp/PreparerUSAddress/ZIPCd007751
ReturnHeader/PreparerPersonGrp/PhoneNum02129730935
ReturnHeader/PreparerPersonGrp/PreparerPersonNm0FRANK BOVE
ReturnHeader/PreparerPersonGrp/SelfEmployedInd0X
ReturnHeader/ReturnTs02022-10-25T11:18:27-07:00
ReturnHeader/ReturnTypeCd0990EZ
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonFirstNm0MICHAEL
ReturnHeader/SigningOfficerGrp/PersonFullName/PersonLastNm0DOROSH
ReturnHeader/TaxPeriodBeginDt02021-01-01
ReturnHeader/TaxPeriodEndDt02021-12-31
ReturnHeader/TaxYr02021

Document Assets

No mirrored PDF or thumbnail assets are attached yet.